All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): rhCollagen
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Large molecule
Partner/Sponsor/Collaborator: Allergan Plc
Deal Size: $103.0 million Upfront Cash: $14.0 million
Deal Type: Collaboration February 08, 2021
Details:
CollPlant has granted Allergan Aesthetics worldwide exclusivity to use its plant-derived recombinant human collagen (rhCollagen) in combination with Allergan Aesthetics' proprietary technologies, for the production and commercialization of dermal and soft tissue fillers.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Cannabinoids
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Cannassure Therapeutics
Deal Size: $0.4 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 18, 2021
Details:
Under the agreement, Cannassure has the exclusive right to use Lipidor’s proprietary drug delivery technology AKVANO®in medicinal cannabis products for the treatment of selected indications such as psoriasis, atopic dermatitis, pain and lesions.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): JT-09
Therapeutic Area: Dermatology Product Name: JT-09
Highest Development Status: Undisclosed Product Type: Peptide
Partner/Sponsor/Collaborator: Titan Pharmaceuticals Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 28, 2020
Details:
Titan has acquired JT Pharma's kappa opioid agonist peptide, JT-09, for use in combination with Titan's ProNeura® long-term, continuous drug delivery technology, for the treatment of chronic pruritus.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TFC-1067
Therapeutic Area: Dermatology Product Name: TFC-1067
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
Study conducted by Dr. Zoe Draelos has been peer reviewed & accepted for publication in the Journal of Cosmetic Dermatology. TFC-1067 demonstrated the ability to lighten dark spots to blend into surrounding skin while preserving overall complexion.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TFC-1067
Therapeutic Area: Dermatology Product Name: TFC-1067
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 13, 2020
Details:
Multiple parameters will be measured including the added effects of the higher concentration of TFC-1067 and a boosted formulation. TFC-1067 has been clinically proven to selectively lighten dark spots and blend them into surrounding skin tone.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dutasteride,Ivermectin,Azithromycin
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Brown University
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 24, 2020
Details:
Breakthrough Discovery By Applied Biology Scientists And Brown University Researchers Paves Way For A Generic Anti-Androgen As A Treatment For Covid-19
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Difluorocyclohexyloxyphenol
Therapeutic Area: Dermatology Product Name: TFC-1067
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 16, 2020
Details:
Sirona has made its first shipment of compound, TFC-1067 to Rodan + Fields. Rodan + Fields will be the first to market for a consumer product utilizing TFC-1067 for the treatment of dyschromia.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
